Intravitreal bevacizumab increases intraocular interleukin-6 levels at 1day after injection in patients with proliferative diabetic retinopathy

Cytokine

Volumn 60, Issue 2, 2012, Pages 535-539

  Jeon, Sohee ^a   Lee, Won Ki ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Interleukin 6; Interleukin 8; Intravitreal bevacizumab; Proliferative diabetic retinopathy; Transforming growth factor beta

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC RETINOPATHY; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RETINA NEOVASCULARIZATION; UPREGULATION; VITRECTOMY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DEMOGRAPHY; DIABETIC RETINOPATHY; EYE; FEMALE; HUMANS; INTERLEUKIN-6; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED;

EID: 84866753235     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.07.005     Document Type: Article

References (51)

1. Congdon N.G., Friedman D.S., Lietman T. Important causes of visual impairment in the world today. JAMA 2003, 290:2057-2060.
2. Klein R., Klein B.E., Moss S.E., Cruickshanks K.J. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998, 105:1801-1815.
3. Demircan N., Safran B.G., Soylu M., Ozcan A.A., Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 2006, 20:1366-1369.
4. Franks W.A., Limb G.A., Stanford M.R., Ogilvie J., Wolstencroft R.A., Chignell A.H., et al. Cytokines in human intraocular inflammation. Curr Eye Res 1992, 11(Supp. l):187-191.
5. Funatsu H., Noma H., Mimura T., Eguchi S., Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009, 116:73-79.
6. Funatsu H., Yamashita H., Ikeda T., Mimura T., Eguchi S., Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003, 110:1690-1696.
7. Adamiec-Mroczek J., Oficjalska-Młyńczak J., Misiuk-Hojło M. Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: analysis of vitreous samples. Cytokine 2010, 49:269-274.
8. Arjamaa O., Pöllönen M., Kinnunen K., Ryhänen T., Kaarniranta K. Increased IL-6 levels are not related to NF-κB or HIF-1α transcription factors activity in the vitreous of proliferative diabetic retinopathy. J Diabetes Complications 2011, 25:393-397.
9. Hernandez C., Segura R.M., Fonollosa A., Carrasco E., Francisco G., Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005, 22:719-722.
10. Petrovič M.G., KoroŠec P., KoŠnik M., Hawlina M. Association of preoperative vitreous IL-8 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy. Acta Ophthalmol 2010, 88:e311-e316.
11. Petrovic M.G., Korosec P., Kosnik M., Hawlina M. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2007, 143:175-176.
12. Pfeiffer A., Spranger J., Meyer-Schwickerath R., Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes 1997, 46(Suppl. 2):S26-S30.
13. Elner S.G., Strieter R., Bian Z.M., Kunkel S., Mokhtarzaden L., Johnson M., et al. Interferon-induced protein 10 and interleukin 8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol 1998, 116:1597-1601.
14. Murugeswari P., Shukla D., Rajendran A., Kim R., Namperumalsamy P., Muthukkaruppan V. Proinflammatory cytokines and angiogenic and antiangiogenic factors in vitreous of patients with proliferative diabetic retinopathy and Eales' disease. Retina 2008, 28:817-824.
15. Elner S.G., Elner V.M., Jaffe G.J., Stuart A., Kunkel S.L., Strieter R.M. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995, 14:1045-1053.
16. Witmer A.N., Vrensen G.F., Van Noorden C.J., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003, 22:1-29.
17. Nguyen Q.D., Shah S.M., Heier J.S., Do D.V., Lim J., Boyer D., et al. READ-2 study group. Primary end point (6months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009, 116:2175-2181.
18. Goyal S., Lavalley M., Subramanian M.L. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011, 249:15-27.
19. Spaide R.F., Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative retinopathy complicated by vitreous hemorrhage. Retina 2006, 26:275-278.
20. Jorge R., Costa R.A., Calioli D., Cintra L.P., Scott I.U. Intravitreal bevacizumab (avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006, 26:1006-1013.
21. Yeoh J., Williams C., Allen P., Buttery R., Chiu D., Clark B., et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 2008, 36:449-454.
22. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008, 99:1501-1506.
23. Forooghian F., Kertes P.J., Eng K.T., Agrón E., Chew E.Y. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci 2010, 51:2388-2392.
24. Matsuyama K., Ogata N., Jo N., Shima C., Matsuoka M., Matsumura M. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol 2009, 53:243-248.
25. Sawada O., Kawamura H., Kakinoki M., Sawada T., Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007, 125:1363-1366.
26. Kramer M., Dadon S., Hasanreisoglu M., Monselise Y., Avraham B.R., Feldman A., et al. Proinflammatory cytokines in a mouse model of central retinal artery occlusion. Mol Vis 2009, 15:885-894.
27. Hangai M., Yoshimura N., Honda Y. Increased cytokine expression in rat retina following transient ischemia. Ophthal Res 1996, 28:248-254.
28. Yan S.F., Tritto I., Pinsky D., Liao H., Huang J., Fuller G., et al. Induction of interleukin-6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem 1995, 270:11463-11471.
29. Frangogiannis N.G., Lindsey M.L., Michael L.H. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 1998, 98:699-710.
30. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
31. Mateo R.B., Reichner J.S., Albina J.E. Interleukin-6 activity in wounds. Am J Physiol Regul Integr Comp Physiol 1994, 266:1840-1844.
32. Motro B., Itin A., Sachs L., Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990, 87:3092-3096.
33. Holzinger C., Weissinger E., Zuckermann A., Imhof M., Kink F., Schöllhammer A., et al. Effects of interleukin-1,-2,-4,-6, interferon-gamma and granulocyte/macrophage colony stimulating factor on human vascular endothelial cells. Immunol Lett 1993, 35:109-117.
34. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol Today 1990, 11:443-449.
35. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271:736-741.
36. Frei K., Malipiero U.V., Leist T.P., Zinkernagel R.M., Schwab M.E., Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 1989, 19:689-694.
37. Barres B.A., Schmid R., Sendnter M., Raff M.C. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 1993, 118:283-295.
38. Legos J.J., Whitmore R.G., Erhardt J.A., Parsons A.A., Tuma R.F., Barone F.C. Quantitative changes in interleukin proteins following focal stroke in the rat. Neurosci Lett 2000, 282:189-192.
39. Loddick S.A., Rothwell N.J. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1998, 18:176-179.
40. Fisher J., Mizrahi T., Schori H., Yoles E., Levkovitch-Verbin H., Haggiag S., et al. Increased post-traumatic survival of neurons in IL-6 knockout mice on a background of EAE susceptibility. J Neuroimmunol 2001, 119:1-9.
41. Saika S. TGF-beta pathobiology in the eye. Lab Invest 2006, 86:106-115.
42. Van Geest R.J., Klaassen I., Vogels I.M., Van Noorden C.J., Schlingemann R.O. Differential TGF-{beta} signaling in retinal vascular cells: a role in diabetic retinopathy?. Invest Ophthalmol Vis Sci 2010, 51:1857-1865.
43. Baggiolini M., Walz A., Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989, 84:1045-1049.
44. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
45. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001, 12:375-391.
46. Arjamaa O., Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006, 83:473-483.
47. Rizzo S., Genovesi-Ebert F., Di Bartolo E., Vento A., Miniaci S., Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008, 246:837-842.
48. Ahmadieh H., Shoeibi N., Entezari M., Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009, 116:1943-1948.
49. da R Lucena D., Ribeiro J.A., Costa R.A., Barbosa J.C., Scott I.U., de Figueiredo-Pontes L.L., et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009, 93:688-691.
50. Romano M.R., Gibran S.K., Marticorena J., Wong D., Heimann H. Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?. Eye (London) 2009, 23:1698-1701.
51. di Lauro R., De Ruggiero P., di Lauro R., di Lauro M.T., Romano M.R. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010, 248:785-791.